Sodium Polystyrene Sulfonate

The dosage of Sodium Polystyrene Sulfonate must be individualized based on the severity of the hyperkalemia and the patient's clinical response.

• Oral Administration: The typical adult dose is 15 grams to 60 grams per day. This is usually administered as a single 15g dose one to four times daily. Each 15g dose is typically mixed in 20mL to 100mL of water or a flavored syrup to improve palatability.
• Rectal Administration: For patients who cannot tolerate oral medication, 30 grams to 50 grams may be administered every 6 hours as a retention enema. The resin should be mixed in approximately 100mL to 200mL of an aqueous vehicle (such as water or 10% dextrose).

Sodium Polystyrene Sulfonate is used in children, but the dosage is strictly calculated based on body weight.

• General Pediatric Dose: The standard calculation is 1 gram of resin per kilogram of body weight per dose.
• Frequency: This may be given every 6 hours depending on the urgency of the potassium reduction.
• Neonatal Warning: Extreme caution is required in newborns, especially premature infants. In neonates, the drug should only be administered rectally, and the lowest effective dose should be used to prevent intestinal necrosis (tissue death) associated with reduced gut motility.

Renal Impairment

No dosage adjustment of the resin itself is required for renal impairment, as the drug is not absorbed or excreted by the kidneys. However, because these patients are at high risk for sodium overload, healthcare providers must monitor for signs of fluid retention and congestive heart failure.

Hepatic Impairment

No specific adjustments are required for patients with liver disease, as the drug does not undergo hepatic metabolism.

Elderly Patients

Elderly patients are at a higher risk for fecal impaction and intestinal obstruction. Lower initial doses and careful monitoring of bowel frequency are recommended for patients over the age of 65.

1. 1Preparation: If using the powder, always mix it with the volume of fluid prescribed by your doctor. Do not inhale the powder, as it can irritate the lungs.
2. 2Avoid Heat: Do not heat the suspension or mix it with hot foods/liquids, as heat can change the resin's chemical properties and reduce its effectiveness.
3. 3Positioning: When taking the oral suspension, stay upright for at least 30 to 60 minutes to prevent aspiration or esophageal irritation.
4. 4Rectal Use: For enemas, the patient should lie on their left side with knees drawn up. The fluid should be retained in the colon for at least 30 to 60 minutes (and ideally several hours) to allow for sufficient ion exchange.
5. 5Timing with Other Meds: Do not take other oral medications within 3 hours before or 3 hours after taking SPS (see 'Interactions' for more details).

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to 'catch up,' as this increases the risk of bowel obstruction and dangerously low potassium levels.

An overdose of Sodium Polystyrene Sulfonate can lead to severe hypokalemia (dangerously low potassium). Symptoms include extreme muscle weakness, leg cramps, confusion, and heart palpitations. It can also cause severe constipation or fecal impaction. If an overdose is suspected, contact a poison control center or seek emergency medical care immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as potassium levels can rise rapidly and dangerously.

Because Sodium Polystyrene Sulfonate works entirely within the digestive tract, the most common side effects are gastrointestinal in nature.

• Constipation: This is the most frequent issue. The resin can become thick and difficult to pass, especially in patients who are dehydrated or have low activity levels.
• Nausea and Vomiting: Many patients find the sandy, gritty texture of the suspension difficult to swallow, which can lead to stomach upset.
• Loss of Appetite (Anorexia): A general feeling of fullness or gastric discomfort may occur.

• Diarrhea: While constipation is more common, some formulations containing sorbitol may cause loose stools or diarrhea.
• Gastric Irritation: Some patients report a 'burning' sensation in the stomach or esophagus.
• Fecal Impaction: This occurs when the resin hardens into a mass in the colon that cannot be passed naturally, often requiring medical intervention.

• Intestinal Necrosis: This is the most feared rare complication. It involves the death of intestinal tissue and can be fatal. It has been historically linked to the combination of SPS and sorbitol.
• Bezoar Formation: In rare cases, the resin can clump together with food particles to form a solid mass (bezoar) in the stomach or intestines.
• Aspiration Pneumonitis: If the suspension is accidentally inhaled into the lungs, it can cause severe lung inflammation.

> Warning: Stop taking Sodium Polystyrene Sulfonate and call your doctor immediately if you experience any of these serious symptoms:

1. 1Severe Abdominal Pain: This could indicate a bowel obstruction, perforation, or intestinal necrosis.
2. 2Bloody or Black, Tarry Stools: These are signs of internal bleeding or tissue damage in the gastrointestinal tract.
3. 3Extreme Muscle Weakness or Paralysis: This may indicate that potassium levels have dropped too low (hypokalemia).
4. 4Confusion and Irritability: These can be signs of electrolyte imbalances, including high sodium or low magnesium.
5. 5Severe Swelling (Edema): Because the resin releases sodium into the body, it can cause fluid retention, leading to swelling in the legs, ankles, or shortness of breath (signs of heart failure).

Prolonged use of Sodium Polystyrene Sulfonate can lead to chronic electrolyte imbalances. Specifically, because the resin is not perfectly selective for potassium, it can also bind to and remove calcium and magnesium. Long-term users may develop hypocalcemia (low calcium) and hypomagnesemia (low magnesium), which can affect bone health and nerve function. Regular blood monitoring is essential for anyone using this medication for more than a few days.

While Sodium Polystyrene Sulfonate does not have a formal 'Black Box' warning in the traditional sense on all generic labels, the FDA issued a significant Safety Communication in 2009 and updated it in 2011. This warning highlights the risk of Intestinal Necrosis. The FDA noted that cases of colonic necrosis and other serious gastrointestinal adverse events (including perforation and obstruction) have been reported, particularly when SPS is administered with sorbitol. The warning states that healthcare providers should weigh the benefits of using SPS against these risks, especially in patients with impaired gastrointestinal motility.

Report any unusual symptoms, especially changes in bowel habits or new abdominal pain, to your healthcare provider immediately.

Sodium Polystyrene Sulfonate is a potent medication that significantly alters the body's electrolyte balance. It is not a 'simple' laxative or supplement; it is a chemical resin that must be managed carefully. The most critical safety consideration is the health of the patient's gastrointestinal tract. If the bowels are not moving normally, the drug can accumulate and cause catastrophic injury to the intestinal wall.

No formal FDA black box warnings are currently mandated for Sodium Polystyrene Sulfonate. However, the FDA-mandated 'Warnings' section of the label carries nearly equivalent weight regarding Gastrointestinal Stenosis and Intestinal Necrosis. These warnings emphasize that the drug should not be used in patients who do not have normal bowel function, including those with recent bowel surgery or those taking opioids that cause severe constipation.

• Gastrointestinal Injury: There have been reports of intestinal bleeding, ischemic colitis (reduced blood flow to the colon), and rectal mucosal injury. Patients with inflammatory bowel disease (IBD) or a history of bowel obstruction are at significantly higher risk.
• Sodium Overload: Each gram of SPS contains approximately 100mg (4.1 mEq) of sodium. A standard 60g daily dose provides 6,000mg of sodium. This is significantly higher than the recommended daily intake for most people. This can lead to severe fluid retention, worsening of high blood pressure, and can trigger congestive heart failure in susceptible individuals.
• Electrolyte Imbalance: While the goal is to lower potassium, the resin can also lower calcium and magnesium levels. This can lead to muscle tetany (spasms) or cardiac issues. Conversely, it can cause hypernatremia (excessively high sodium).
• Aspiration Risk: Due to its gritty texture, there is a risk of the medication being inhaled into the lungs, especially in patients with a weakened gag reflex or those who are sedated. This can lead to 'resin pneumonia.'

Patients taking Sodium Polystyrene Sulfonate require frequent laboratory monitoring, often daily in an inpatient setting. Key tests include:

• Serum Potassium: To ensure the drug is working and to prevent hypokalemia.
• Serum Sodium: To monitor for sodium overload.
• Calcium and Magnesium: To detect unintended depletion of these minerals.
• Electrocardiogram (ECG): To monitor for heart rhythm changes associated with potassium fluctuations.

Sodium Polystyrene Sulfonate does not typically cause drowsiness or cognitive impairment. Most patients can drive or operate machinery safely. However, if you experience extreme weakness or confusion due to electrolyte shifts, you should avoid these activities and contact your doctor.

There is no direct chemical interaction between alcohol and Sodium Polystyrene Sulfonate. However, alcohol can contribute to dehydration and electrolyte imbalances, which can complicate the management of hyperkalemia. It is generally advised to limit alcohol intake while being treated for high potassium.

SPS is usually discontinued once potassium levels reach a safe range (typically below 5.0 mEq/L). There is no withdrawal syndrome associated with stopping the drug, but potassium levels may rise again if the underlying cause of the hyperkalemia (such as kidney disease or certain medications) is not addressed.

> Important: Discuss all your medical conditions, especially heart failure, high blood pressure, or bowel problems, with your healthcare provider before starting Sodium Polystyrene Sulfonate.

• Sorbitol (Concentrated): Historically, SPS was mixed with high concentrations of sorbitol to prevent constipation. However, the FDA now warns against the concomitant use of SPS and concentrated sorbitol due to the high risk of intestinal necrosis. While many premixed versions still contain small amounts of sorbitol, the use of additional concentrated sorbitol is generally contraindicated.

• Digitalis (Digoxin): This is a critical interaction. Sodium Polystyrene Sulfonate lowers potassium. If potassium levels drop too low while a patient is taking Digoxin, the risk of digitalis toxicity increases significantly. This can lead to life-threatening heart arrhythmias. Patients on both drugs require very frequent potassium monitoring.
• Cation-Donating Antacids and Laxatives: Drugs like magnesium hydroxide (Milk of Magnesia), calcium carbonate (Tums), or aluminum hydroxide can interfere with the resin. These cations (magnesium, calcium, aluminum) can bind to the resin, preventing it from binding to potassium. This reduces the drug's effectiveness and can also cause a condition called systemic alkalosis.

• Levothyroxine (Synthroid): Sodium Polystyrene Sulfonate can bind to thyroid hormones in the gut, preventing their absorption. This can lead to hypothyroidism. It is recommended to separate the administration of thyroid medication and SPS by at least 4 hours.
• Lithium: The resin may bind to lithium, potentially reducing its blood levels and effectiveness in treating bipolar disorder.
• Other Oral Medications: Because SPS is a non-specific binder, it has the potential to bind to almost any oral medication taken at the same time. This can significantly reduce the amount of other medications that reach the bloodstream.

• High-Potassium Foods: Eating foods high in potassium (bananas, oranges, potatoes, spinach) while taking SPS is counterproductive. The resin will bind to the potassium in the food rather than the excess potassium already in your body. Patients are typically placed on a low-potassium diet.
• Orange Juice: Do not mix SPS powder with orange juice or other fruit juices, as these are naturally high in potassium and will neutralize the resin before it even enters your system.

• Potassium Supplements: It is critical to stop all potassium supplements and salt substitutes (which often contain potassium chloride) while taking SPS.
• Calcium/Magnesium Supplements: Like antacids, these can bind to the resin and reduce its ability to remove potassium.

Sodium Polystyrene Sulfonate does not typically interfere with the chemical assays used in lab tests, but it will directly change the results of electrolyte panels (Potassium, Sodium, Calcium, Magnesium) as part of its intended therapeutic effect.

Management Strategy: To avoid most drug-drug interactions, the FDA recommends that Sodium Polystyrene Sulfonate be administered at least 3 hours before or 3 hours after any other oral medications. For patients with gastroparesis (slow stomach emptying), this window should be increased to 6 hours.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids and laxatives.

Sodium Polystyrene Sulfonate must NEVER be used in the following circumstances:

1. 1Hypokalemia: If a patient already has low potassium levels (less than 3.5 mEq/L), using SPS can drop levels to a point that causes cardiac arrest.
2. 2Obstructive Bowel Disease: If the intestines are blocked, the resin cannot pass through. It will accumulate, harden, and likely cause a bowel perforation (a hole in the intestine), which is a surgical emergency.
3. 3Neonates with Reduced Gut Motility: Newborns, especially those who are premature or have low birth weight, are at extreme risk for necrotizing enterocolitis (NEC) if given SPS orally or if they have slow bowel movements.
4. 4Hypersensitivity: Anyone with a known allergy to polystyrene sulfonate resins should not use this medication.

In these conditions, the drug should only be used if the benefits clearly outweigh the risks, and under intense monitoring:

• Congestive Heart Failure (CHF): The high sodium load can cause fluid overload, leading to pulmonary edema (fluid in the lungs).
• Severe Hypertension: The sodium content can make blood pressure very difficult to control.
• Recent Bowel Surgery: The risk of intestinal necrosis and perforation is significantly higher in the weeks following abdominal surgery.
• Edema: Patients already experiencing significant swelling are at risk for worsening symptoms due to sodium retention.

There are no commonly used drugs that share the exact chemical structure of Sodium Polystyrene Sulfonate, so cross-sensitivity is rare. However, patients who have had adverse reactions to other ion-exchange resins (like Cholestyramine) should be monitored closely for similar gastrointestinal sensitivities.

> Important: Your healthcare provider will evaluate your complete medical history, including your heart health and bowel function, before prescribing Sodium Polystyrene Sulfonate.

Sodium Polystyrene Sulfonate is classified as FDA Pregnancy Category C (under the old system). Because the drug is not absorbed systemically, it is not expected to cause direct fetal harm or birth defects. However, the drug can cause significant changes in the mother's electrolyte levels and fluid balance. Severe maternal hypokalemia or sodium-induced hypertension could theoretically affect placental blood flow. Use in pregnancy should be limited to cases where the mother's hyperkalemia poses a greater risk than the drug's potential for causing fluid shifts.

It is not known whether Sodium Polystyrene Sulfonate is excreted in human milk. However, because the drug is not absorbed into the mother's bloodstream, it is physically impossible for the resin itself to enter the breast milk. The primary concern for nursing mothers is the potential for the drug to alter the electrolyte composition of the milk or the mother's overall hydration status. Most clinical experts consider it compatible with breastfeeding, but monitoring of the infant for any signs of GI distress is prudent.

SPS is used in children, but with extreme caution. The risk of fecal impaction is higher in younger children. In neonates, the drug should not be given by mouth. Rectal administration in infants requires careful technique to ensure the resin is fully expelled, preventing it from drying and causing a blockage. The drug is not approved for use in infants with 'ileus' (where the bowels have stopped moving).

Patients over the age of 65 are at the highest risk for complications from Sodium Polystyrene Sulfonate.

• Bowel Motility: Older adults naturally have slower digestion, increasing the risk of impaction.
• Polypharmacy: Elderly patients are often on multiple medications (like blood pressure pills or diuretics) that can interact with SPS.
• Heart Health: A higher prevalence of CHF in this population makes the sodium load from the resin particularly dangerous.

While the drug is used to treat a complication of renal impairment, these patients are paradoxically the most sensitive to its side effects. Since their kidneys cannot excrete the sodium released by the resin, they are at maximum risk for hypernatremia and fluid overload. Many patients with end-stage renal disease (ESRD) may require dialysis to manage potassium if SPS is too risky or ineffective.

No specific adjustments are needed for liver disease, but patients with 'ascites' (fluid in the abdomen) from cirrhosis should be monitored closely, as the sodium load can worsen fluid accumulation.

> Important: Special populations, particularly the elderly and neonates, require individualized medical assessment and lower starting doses.

Sodium Polystyrene Sulfonate is a large, insoluble, non-digestible polymer. Its chemical structure consists of a polystyrene backbone with sulfonic acid functional groups. These sulfonic acid groups are 'cationic exchangers.' In the manufacturing process, these groups are saturated with sodium ions.

When the resin enters the gastrointestinal tract, it encounters an environment rich in various cations, including potassium (K+), calcium (Ca2+), and magnesium (Mg2+). The resin has a higher affinity for these ions than it does for sodium (Na+). Through a process of diffusion and ion exchange, the sodium ions leave the resin and enter the intestinal fluid, while potassium ions move from the fluid and bind to the resin.

Mathematically, 1 gram of the resin has an in vitro exchange capacity of about 3.1 mEq of potassium. However, in the human body (in vivo), the actual exchange is closer to 1 mEq of potassium per 1 gram of resin, because some of the resin's capacity is taken up by calcium and magnesium ions.

• Onset of Action: 2 to 12 hours (Oral); slightly faster for rectal administration.
• Duration of Effect: The effect lasts as long as the resin remains in the colon. Once the resin is excreted, the removal of potassium stops.
• Dose-Response: The reduction in serum potassium is generally proportional to the dose, but it is heavily influenced by the patient's existing potassium levels and gut transit time.

| Parameter | Value |

|---|---|

| Bioavailability | 0% (Not absorbed) |

| Protein Binding | 0% |

| Half-life | N/A (Dependent on bowel transit) |

| Tmax | 2 - 12 hours (onset of effect) |

| Metabolism | None |

| Excretion | 100% Fecal |

• Molecular Formula: (C8H7SO3Na)n
• Solubility: Insoluble in water and organic solvents.
• Appearance: Fine, light brown to gold powder.
• Structure: A cross-linked polymer of styrene and divinylbenzene, sulfonated and neutralized with sodium.

Sodium Polystyrene Sulfonate is a Cation-Exchange Resin. It is the oldest member of the potassium binder class. Newer medications in this class include Patiromer (Veltassa) and Sodium Zirconium Cyclosilicate (Lokelma), which were designed to have higher selectivity for potassium and fewer gastrointestinal side effects than SPS.